# US 8,465,746 B2 · Compositions and methods for treatment, research and therapeutic applications for malaria

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,465,746 B2
- Document ID: US8465746B2
- Status: Granted
- Kind: B2
- Application number: 12/255,902
- Filed: 2008-10-22
- Published: 2009-05-28
- Granted: 2013-06-18
- Earliest claimed: 2007-10-22
- Assignees: Northwestern University
- Applicants: Kasturi Haldar; Pamela Tamez; Souvik Bhattacharjee
- Inventors: Kasturi Haldar; Pamela Tamez; Souvik Bhattacharjee
- Web page: https://patentgrep.com/patent/US8465746B2

## CPC

- A61K 39/0005: {Vertebrate antigens (from snakes A61K39/38)}
- A61K 39/015: Hemosporidia antigens, e.g. Plasmodium antigens
- A61P 33/00: Antiparasitic agents
- G01N 33/56905: {Protozoa}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- G01N 2333/445: Plasmodium
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention provides anti-Plasmodium immunogenic compositions comprising EVP1 (PFD0495c) or an antigenic portion thereof, as well as methods of immunizing against malaria employing these compositions. In other embodiments, the present invention provides methods of identifying Plasmodium infection employing agents that bind to EVP1 or an antibody generated thereto.

## Claims

### Claim 1

A method for eliciting an immune response in an subject, comprising: administering a composition to a subject such that said subject manifests an immune response, wherein said composition comprises an isolated protein selected from the group consisting of: i) an isolated peptide comprising the amino acid sequence as set forth in SEQ ID NO: 17, or ii) an isolated protein comprising the amino acid sequence selected from SEQ ID NOs: 7-12.

### Claim 2 (depends on 1)

The method of claim 1, wherein said isolated protein is conjugated to a hapten or other immune stimulating moiety.

### Claim 3 (depends on 1)

The method of claim 1, wherein said composition further comprises an adjuvant and/or physiological tolerable buffer.

### Claim 4 (depends on 1)

The method of claim 1, wherein said subject is a human.

### Claim 5 (depends on 1)

The method of claim 1, wherein said Plasmodium infection is Plasmodium falciparum infection.